Clinical trials
Depression clinical trials
A common mood disorder causing persistent sadness and loss of interest. We’re tracking 1,509 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05828056Recruiting
Predicting mood episodes in bipolar disorder with a smartwatch
This study uses a smartwatch and smartphone to track daily patterns and predict when manic or depressive episodes might happen in people with bipolar disorder. It aims to help patients and doctors better manage the condition.
TaipeiAges 20–60 - NCT07227454RecruitingPhase 3
Esketamine for teens with severe depression and suicidal thoughts
This trial tests if esketamine (a nasal spray) can quickly reduce symptoms of major depression and suicidal thoughts in teenagers who need urgent hospital care.
Birmingham, AlabamaAges 12–17 - NCT07573176RecruitingPhase 3
Seltorexant for Depression in Adults and Older Adults
This study tests a new medication called seltorexant as a standalone treatment for major depression. The trial is for adults and older adults who have depression that hasn't improved with other antidepressants or who haven't tried them yet.
Bellflower, CaliforniaAges 18–74 - NCT07716098RecruitingPhase 3
Esketamine nasal spray for treatment-resistant depression
This study tests esketamine nasal spray versus a placebo in adults with depression that has not improved after trying at least two other antidepressants. It aims to see if the spray can help when standard pills have not worked.
Skokie, IllinoisAges 18 years+ - NCT06518720RecruitingPhase 2
Psilocybin for Chronic Nerve Pain and Depression
This trial tests whether psilocybin (a psychedelic medication) can help people who have both chronic nerve pain and depression that hasn't responded to standard treatments. The goal is to see if it can reduce pain and improve mood.
Toronto, OntarioAges 18–65 - NCT07737990Enrolling by invitation
Psilocybin group therapy for treatment-resistant depression
This trial tests whether psilocybin-assisted group therapy can help people whose depression hasn't improved with other treatments. You must have already completed a prior psilocybin study to join this group.
Toronto, OntarioAges 18 years+ - NCT06818734Recruiting
Testing a tool for postpartum depression screening
This trial tests a tool that helps doctors screen for postpartum depression during pregnancy. You may be eligible if you are at least 20 weeks pregnant and receive care at a participating clinic.
Brooklyn, New YorkAges 18 years+ - NCT07413874Recruiting
Music therapy over video for depression and hormone disorder
This trial tests if telehealth music therapy can help adults who have both an endocrine autoimmune disease and depression. You'll join sessions from home using Zoom.
Boone, North CarolinaAges 18–65 - NCT06706232RecruitingPhase 2
Psilocybin for Depression and Suicidal Thoughts in Bipolar II
This trial tests if two doses of psilocybin, given under medical supervision, are safe and acceptable for people with Bipolar II disorder who have mild to moderate depression and certain suicidal thoughts. The goal is to see if it may help improve mood and reduce suicidal thinking.
Houston, TexasAges 25–70 - NCT07552246RecruitingPhase 4
Acupuncture vs medication for depression and anxiety
This study compares acupuncture with standard medication for reducing depression, anxiety, and related sleep problems. It aims to see if acupuncture is a helpful alternative for people in China who are struggling with these conditions.
Kunshan, JiangsuAges 18–65 - NCT05671419Recruiting
Mindful self-compassion training for anxiety and depression
This study tests whether a structured “mindful self-compassion” program can reduce symptoms of anxiety disorders or depression. It’s meant to help by improving how you relate to yourself during difficult thoughts and feelings.
Washington D.C., District of ColumbiaAges 18–75 - NCT07211438RecruitingPhase 2
Psilocybin with Monitors for Treatment-Resistant Depression
This study tests whether trained monitors improve the safety and outcomes of psilocybin therapy for people with depression that hasn't responded to other treatments. Participants will receive psilocybin in a supervised setting and will need to temporarily stop other psychiatric medications.
Toronto, OntarioAges 18–70 - NCT06567340Recruiting
AI-guided care for depression in talking therapies
This trial tests whether an AI tool can help therapists choose the best treatment for depression. If you are 18 or older and have significant depression symptoms (PHQ-9 score of 10 or more), you may be able to join if you are already being treated at a participating Talking Therapies service.
Darlington, DurhamAges 18 years+ - NCT07105397Recruiting
AI assistant for managing depression
This study tests a conversational AI system designed to help manage depression. It may recommend treatment changes that are reviewed by a clinician, offering a new way to get support.
Fairfax, VirginiaAges 18–85 - NCT06966401RecruitingPhase 3
Long-term safety study of a new depression treatment
This study tests a new oral medication (NBI-1065845) added to your current antidepressant to see if it's safe and tolerable over a long period for people with depression that hasn't fully responded to treatment.
Huntsville, AlabamaAges 18 years+ - NCT07484217RecruitingPhase 3
Testing solriamfetol for depression with daytime sleepiness
This study tests if the drug solriamfetol can help people with major depression who also feel very tired during the day. It aims to improve both mood and daytime sleepiness.
Tucson, ArizonaAges 18–65 - NCT07196501RecruitingPhase 3
Study of a new add-on treatment for depression maintenance
This trial tests a new medication (NBI-1065845) added to your current antidepressant to see if it helps maintain improvement in depression. It is for people whose depression hasn't fully responded to their current oral antidepressant.
Oceanside, CaliforniaAges 18 years+ - NCT07721961RecruitingPhase 3
Study of MI078 for postpartum depression
This trial tests a new medication, MI078, to see if it can help women with postpartum depression. You may qualify if you are between 18 and 45, have given birth within the last year, and are currently experiencing moderate to severe depression that started in late pregnancy or shortly after delivery.
Hefei, AnhuiAges 18–45 - NCT05850689RecruitingPhase 3
Lumateperone add-on for major depression that didn’t improve
This study tests whether adding lumateperone to an antidepressant helps adults with major depressive disorder (MDD) who haven’t improved enough after trying at least two different antidepressants. It may help reduce depressive symptoms more than antidepressants alone.
Huntsville, AlabamaAges 18–65 - NCT07563868Recruiting
Coaching to help ketamine therapy for hard-to-treat depression
This study tests whether adding coaching sessions can help people who are already getting ketamine or esketamine treatment for depression that hasn't responded to other medications. You'd receive weekly coaching calls designed to support your recovery while you continue your regular ketamine clinic visits.
Boston, MassachusettsAges 18 years+ - NCT07055061Recruiting
Music for reducing stress, anxiety and depression
This trial tests if listening to specially designed music can help reduce stress, anxiety and depression. It may be a good option for people who are not currently taking medication or receiving treatment.
Beijing, Beijing MunicipalityAges 18–60 - NCT05977439Recruiting
Brain training for depression recovery
This study uses brain imaging and stimulation to help people with depression learn how to regulate their emotions better. It aims to find out if targeting specific brain networks can improve symptoms.
Charleston, South CarolinaAges 18–65 - NCT07180537Recruiting
Health course for joint and mood conditions
This study tests an online health course that helps improve diet and self-care to support cell health and wellbeing. It is for people with certain rheumatological conditions like rheumatoid arthritis, lupus, or psoriatic arthritis, who also have mood concerns.
Iowa City, IowaAges 18–100 - NCT07610369RecruitingPhase 2
Psilocybin therapy for depression in Parkinson's disease
This study tests whether psilocybin (a psychedelic compound) combined with therapy can reduce depression in people with Parkinson's disease. If you have moderate-to-severe depression and Parkinson's, this trial may offer a new treatment option.
New Haven, ConnecticutAges 40–80
Hear when a new Depression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for depression?
- Yes. Clin2 currently lists 1,509 recruiting depression studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a depression trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a depression trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.